Company intelligence / Profile preview

PairX Bio

Ownership: Private
Development stage: Preclinical

Overview

PairX Bio is a pre-clinical stage biotech company developing next-generation cancer immunotherapies. Their proprietary platform identifies novel, highly prevalent tumor-selective targets—specifically shared antigens from aberrantly spliced proteins—and pairs them with optimal therapeutic modalities to create first-in-class or best-in-class biologics. The company has not yet reported clinical results but has received recognition such as the Amgen Golden Ticket Award and is advancing a robust pipeline targeting large patient populations in areas of unmet need[1][4].

Therapeutic areas: Oncology
Modalities: Biologics (including antibodies and other protein-based therapeutics)Immunotherapies (T cell-based, potentially others)
Industry: Biotech

Partnerships

Duke-NUS Medical School (technology licensing and ongoing collaboration)[3]

Beyond the preview

Go deeper on PairX Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PairX Bio.

Explore the full profile